Gilead Sciences, Inc. $GILD Shares Purchased by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 429.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 65,978 shares of the biopharmaceutical company’s stock after purchasing an additional 53,507 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Gilead Sciences were worth $8,098,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Brighton Jones LLC increased its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC increased its holdings in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Ieq Capital LLC increased its holdings in shares of Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its holdings in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 674 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 63,000 shares of company stock valued at $9,238,250 in the last three months. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GILD shares. Wolfe Research raised their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Needham & Company LLC reissued a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. UBS Group lifted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Truist Financial reaffirmed a “buy” rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Finally, Rothschild & Co Redburn dropped their price objective on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $157.04.

Gilead Sciences Trading Down 1.9%

Shares of NASDAQ GILD opened at $129.58 on Friday. Gilead Sciences, Inc. has a twelve month low of $100.23 and a twelve month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a fifty day simple moving average of $137.76 and a 200-day simple moving average of $133.22. The stock has a market capitalization of $160.88 billion, a PE ratio of 17.65 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.